{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-015453","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.407192+00:00","generated_at":"2026-06-02T06:10:08.333350+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monopar Q1 net loss $1.6M; pivots to radiopharma pipeline, winding down other programs","bullets":["Net loss $1.6M ($0.10/shr) vs $2.4M ($0.19/shr) in Q1 2023.","Cash and short-term investments $8.8M as of Mar 31, 2024, sufficient through June 2025.","Company winding down non-radiopharma programs (camsirubicin, MNPR-202) to focus on MNPR-101 radiopharma.","First-in-human Phase 1 trial of MNPR-101-Zr initiated; targeting MNPR-101-RIT Phase 1 launch by Q4 2024/Q1 2025.","Additional funding will be needed within the next 12 months to support operations beyond current runway."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-015453","json":"https://secwatch.observer/filing/0001437749-24-015453.json","markdown":"https://secwatch.observer/filing/0001437749-24-015453.md","text":"https://secwatch.observer/filing/0001437749-24-015453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/0001437749-24-015453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/mnpr20240502_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:10:08.333350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2fdcebc80506a3a4f63d78eb8faa83a8b6c341b","claim":"Monopar Therapeutics reported first quarter ended March 31, 2024 results: net income $1.6 million, EPS $0.10 per share.","evidence_excerpt":"Net loss for the first quarter of 2024 was $1.6 million or $0.10 per share compared to net loss of $2.4 million or $0.19 per share for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/0001437749-24-015453-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$1.6 million"},{"label":"EPS","value":"$0.10 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}